Somavert Market is estimated to grow at a significant CAGR during the forecast period. Somavert is a human-made protein, similar to the growth hormone of humans. Pegvisomant binds to the body receptor and blocks the effects of the growth hormone. Somavert is typically given without successful symptom treatment after other medications, surgery or radiation have been treated. Somavert is an enzyme or drug that is used to treat the hormone acromegaly that causes excessive growth hormone (EGH) in adults. In body areas such as the hands, feet and face, patients with this disease have large bones. Acromegaly is the result of non-cancerous growth and affects mostly mid-aged adults. The enzyme can inhibit GH expansion as a growth hormone receptor antagonist and return blood insulin growth factor I (IGF-I) levels in patients with acromegaly to normal.
To Request a Sample of our Report on Somavert Market: https://www.omrglobal.com/request-sample/somavert-market
Global awareness of hormone problem drugs and therapies is increasing is the driving factor that is driving the market expansion. The improved overall clinical status of the patient as a result of treatment has contributed significantly to the growth of the market. The rise in the number of patients, particularly among adults, with this rare disease increases the demand for this drug that is expected to significantly boost the market growth. Technological advances and increased R&D expenses in the discovery of innovative products by major manufacturers offer advanced opportunities that boost the market growth.
Somavert (pegvisomant) is a sterile, white lyophilized injector for reconstitution in subcutaneous form. The Somavert packages are supplied with a separate glass vial that includes sterile injection water, USP, a sterile non-pyrogenic water preparation for injection that does not contain a diluent bacteriostatic, antimicrobial agent, and buffer. Somavert (Pegvisomant for injecting) has been approved by the FDA to treat acromegaly in patients who have had or are not appropriate for inadequate response with surgery and radiation therapy and other medical treatments.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segments Covered
- By Type
- By Application
Regions Covered
- North America
- Europe
- Asia-Pacific
- Rest of the world
- Competitive Landscape- Chiasma, Inc., F.Hoffmann La Roche, Ltd., Boehringer Ingelheim International GmbH, Novartis AG, and Ipsen Group., among others.
A full Report of Somavert Market is Available at: https://www.omrglobal.com/industry-reports/somavert-market
Somavert Drug Market by Segments
By Type
- Prefilled
- Non-Prefilled
By application
- Hospital
- Pharmacy
Somavert Drug Market by Regions
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of The World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/somavert-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
